

Francesca Mallamaci

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11656408/publications.pdf>

Version: 2024-02-01

258
papers

17,776
citations

13087

68
h-index

15716

125
g-index

260
all docs

260
docs citations

260
times ranked

13589
citing authors

#	ARTICLE	IF	CITATIONS
1	A Prospective Study of the Prevalence of Primary Aldosteronism in 1,125 Hypertensive Patients. <i>Journal of the American College of Cardiology</i> , 2006, 48, 2293-2300.	1.2	1,236
2	Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. <i>Lancet, The</i> , 2001, 358, 2113-2117.	6.3	993
3	Adiponectin, Metabolic Risk Factors, and Cardiovascular Events among Patients with End-Stage Renal Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2002, 13, 134-141.	3.0	560
4	Plasma Norepinephrine Predicts Survival and Incident Cardiovascular Events in Patients With End-Stage Renal Disease. <i>Circulation</i> , 2002, 105, 1354-1359.	1.6	485
5	Vitamin D levels and patient outcome in chronic kidney disease. <i>Kidney International</i> , 2009, 75, 88-95.	2.6	384
6	Atherosclerotic Renal Artery Stenosis: Epidemiology, Cardiovascular Outcomes, and Clinical Prediction Rules. <i>Journal of the American Society of Nephrology: JASN</i> , 2002, 13, S179-S183.	3.0	379
7	Asymmetrical Dimethylarginine Predicts Progression to Dialysis and Death in Patients with Chronic Kidney Disease: A Competing Risks Modeling Approach. <i>Journal of the American Society of Nephrology: JASN</i> , 2005, 16, 2449-2455.	3.0	352
8	Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure. <i>Lancet, The</i> , 2014, 383, 1831-1843.	6.3	341
9	Left ventricular mass monitoring in the follow-up of dialysis patients: Prognostic value of left ventricular hypertrophy progression. <i>Kidney International</i> , 2004, 65, 1492-1498.	2.6	299
10	Chronic Fluid Overload and Mortality in ESRD. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 2491-2497.	3.0	286
11	Exercise in Patients on Dialysis: A Multicenter, Randomized Clinical Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 1259-1268.	3.0	272
12	Cardiac Natriuretic Peptides Are Related to Left Ventricular Mass and Function and Predict Mortality in Dialysis Patients. <i>Journal of the American Society of Nephrology: JASN</i> , 2001, 12, 1508-1515.	3.0	270
13	The systemic nature of CKD. <i>Nature Reviews Nephrology</i> , 2017, 13, 344-358.	4.1	265
14	Hyperhomocysteinemia predicts cardiovascular outcomes in hemodialysis patients. <i>Kidney International</i> , 2002, 61, 609-614.	2.6	247
15	Prognostic Impact of the Indexation of Left Ventricular Mass in Patients Undergoing Dialysis. <i>Journal of the American Society of Nephrology: JASN</i> , 2001, 12, 2768-2774.	3.0	246
16	Asymmetric Dimethylarginine, C-Reactive Protein, and Carotid Intima-Media Thickness in End-Stage Renal Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2002, 13, 490-496.	3.0	235
17	Detection of Pulmonary Congestion by Chest Ultrasound in Dialysis Patients. <i>JACC: Cardiovascular Imaging</i> , 2010, 3, 586-594.	2.3	232
18	Pulmonary Congestion Predicts Cardiac Events and Mortality in ESRD. <i>Journal of the American Society of Nephrology: JASN</i> , 2013, 24, 639-646.	3.0	221

#	ARTICLE	IF	CITATIONS
19	Inflammation Markers, Adhesion Molecules, and All-Cause and Cardiovascular Mortality in Patients with ESRD: Searching for the Best Risk Marker by Multivariate Modeling. <i>Journal of the American Society of Nephrology</i> : JASN, 2005, 16, S83-S88.	3.0	217
20	Uric Acid and Endothelial Dysfunction in Essential Hypertension. <i>Journal of the American Society of Nephrology</i> : JASN, 2006, 17, 1466-1471.	3.0	202
21	Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients. <i>Kidney International</i> , 2002, 62, 339-345.	2.6	194
22	Phosphate May Promote CKD Progression and Attenuate Renoprotective Effect of ACE Inhibition. <i>Journal of the American Society of Nephrology</i> : JASN, 2011, 22, 1923-1930.	3.0	190
23	Long-term CAPD patients are volume expanded and display more severe left ventricular hypertrophy than haemodialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2001, 16, 1459-1464.	0.4	181
24	Prognostic Value of Echocardiographic Indicators of Left Ventricular Systolic Function in Asymptomatic Dialysis Patients. <i>Journal of the American Society of Nephrology</i> : JASN, 2004, 15, 1029-1037.	3.0	180
25	Inflammation is associated with carotid atherosclerosis in dialysis patients. <i>Journal of Hypertension</i> , 2000, 18, 1207-1213.	0.3	179
26	Identification of the Uric Acid Thresholds Predicting an Increased Total and Cardiovascular Mortality Over 20 Years. <i>Hypertension</i> , 2020, 75, 302-308.	1.3	177
27	Inflammation and outcome in end-stage renal failure: Does female gender constitute a survival advantage?. <i>Kidney International</i> , 2002, 62, 1791-1798.	2.6	175
28	Traditional and emerging cardiovascular risk factors in end-stage renal disease. <i>Kidney International</i> , 2003, 63, S105-S110.	2.6	168
29	Prognostic Value of Ultrasonographic Measurement of Carotid Intima Media Thickness in Dialysis Patients. <i>Journal of the American Society of Nephrology</i> : JASN, 2001, 12, 2458-2464.	3.0	166
30	Adrenalectomy Lowers Incident Atrial Fibrillation in Primary Aldosteronism Patients at Long Term. <i>Hypertension</i> , 2018, 71, 585-591.	1.3	149
31	The double challenge of resistant hypertension and chronic kidney disease. <i>Lancet</i> , The, 2015, 386, 1588-1598.	6.3	147
32	SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 208-230.	0.4	147
33	Diagnostic potential of cardiac natriuretic peptides in dialysis patients. <i>Kidney International</i> , 2001, 59, 1559-1566.	2.6	145
34	Troponin is related to left ventricular mass and predicts all-cause and cardiovascular mortality in hemodialysis patients. <i>American Journal of Kidney Diseases</i> , 2002, 40, 68-75.	2.1	144
35	Comparison of the Captopril and the Saline Infusion Test for Excluding Aldosterone-Producing Adenoma. <i>Hypertension</i> , 2007, 50, 424-431.	1.3	142
36	Hypertension in dialysis patients: a consensus document by the European Renal and Cardiovascular Medicine (EURECA-m) working group of the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) and the Hypertension and the Kidney working group of the European Society of Hypertension (ESH)*. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, 620-640.	0.4	133

#	ARTICLE	IF	CITATIONS
37	Low Triiodothyronine: A New Facet of Inflammation in End-Stage Renal Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2005, 16, 2789-2795.	3.0	132
38	Comparison of Calcium Acetate and Sevelamer on Vascular Function and Fibroblast Growth Factor 23 in CKD Patients: A Randomized Clinical Trial. <i>American Journal of Kidney Diseases</i> , 2012, 59, 177-185.	2.1	128
39	The Agreement between Auscultation and Lung Ultrasound in Hemodialysis Patients: The LUST Study. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 2005-2011.	2.2	124
40	Norepinephrine and Concentric Hypertrophy in Patients With End-Stage Renal Disease. <i>Hypertension</i> , 2002, 40, 41-46.	1.3	123
41	Endothelial Dysfunction in Chronic Kidney Disease, from Biology to Clinical Outcomes: A 2020 Update. <i>Journal of Clinical Medicine</i> , 2020, 9, 2359.	1.0	123
42	Nocturnal Hypoxemia Predicts Incident Cardiovascular Complications in Dialysis Patients. <i>Journal of the American Society of Nephrology: JASN</i> , 2002, 13, 729-733.	3.0	122
43	Autonomic neuropathy is linked to nocturnal hypoxaemia and to concentric hypertrophy and remodelling in dialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2001, 16, 70-77.	0.4	121
44	Nocturnal hypoxemia, night-day arterial pressure changes and left ventricular geometry in dialysis patients. <i>Kidney International</i> , 1998, 53, 1078-1084.	2.6	120
45	Novel Cardiovascular Risk Factors in End-Stage Renal Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2004, 15, 77S-80.	3.0	120
46	ACE Inhibition Is Renoprotective among Obese Patients with Proteinuria. <i>Journal of the American Society of Nephrology: JASN</i> , 2011, 22, 1122-1128.	3.0	119
47	Pulmonary Hypertension in CKD. <i>American Journal of Kidney Diseases</i> , 2013, 61, 612-622.	2.1	119
48	Prognostic value of combined use of biomarkers of inflammation, endothelial dysfunction, and myocardial pathology in patients with ESRD. <i>Kidney International</i> , 2005, 67, 2330-2337.	2.6	116
49	Prognostic value of 24-hour ambulatory blood pressure monitoring and of night/day ratio in nondiabetic, cardiovascular events-free hemodialysis patients. <i>Kidney International</i> , 2005, 68, 1294-1302.	2.6	114
50	Adiponectin is markedly increased in patients with nephrotic syndrome and is related to metabolic risk factors. <i>Kidney International</i> , 2003, 63, S98-S102.	2.6	110
51	Paricalcitol and Endothelial Function in Chronic Kidney Disease Trial. <i>Hypertension</i> , 2014, 64, 1005-1011.	1.3	106
52	Dissecting Inflammation in ESRD: Do Cytokines and C-Reactive Protein Have a Complementary Prognostic Value for Mortality in Dialysis Patients?. <i>Journal of the American Society of Nephrology: JASN</i> , 2006, 17, S169-S173.	3.0	101
53	Inflammation and Asymmetric Dimethylarginine for Predicting Death and Cardiovascular Events in ESRD Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 1714-1721.	2.2	98
54	Subclinical hypothyroidism is linked to micro-inflammation and predicts death in continuous ambulatory peritoneal dialysis. <i>Nephrology Dialysis Transplantation</i> , 2006, 22, 538-544.	0.4	94

#	ARTICLE	IF	CITATIONS
55	Analysis of the Relationship between Norepinephrine and Asymmetric Dimethyl Arginine Levels among Patients with End-Stage Renal Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2004, 15, 435-441.	3.0	93
56	Prediction of left ventricular geometry by clinic, pre-dialysis and 24-h ambulatory BP monitoring in hemodialysis patients. <i>Journal of Hypertension</i> , 1999, 17, 1751-1758.	0.3	92
57	Left atrial volume in end-stage renal disease: a prospective cohort study. <i>Journal of Hypertension</i> , 2006, 24, 1173-1180.	0.3	90
58	Prospective evaluation of the saline infusion test for excluding primary aldosteronism due to aldosterone-producing adenoma. <i>Journal of Hypertension</i> , 2007, 25, 1433-1442.	0.3	90
59	Hypertension in Chronic Kidney Disease Part 2. <i>Hypertension</i> , 2016, 67, 1102-1110.	1.3	86
60	Sympathetic Nerve Traffic Activation in Essential Hypertension and Its Correlates. <i>Hypertension</i> , 2018, 72, 483-491.	1.3	79
61	Left Atrial Volume Monitoring and Cardiovascular Risk in Patients with End-Stage Renal Disease: A Prospective Cohort Study. <i>Journal of the American Society of Nephrology: JASN</i> , 2007, 18, 1316-1322.	3.0	78
62	Clinical management of the uraemic syndrome in chronic kidney disease. <i>Lancet Diabetes and Endocrinology</i> , 2016, 4, 360-373.	5.5	78
63	Inflammation and Atherosclerosis in End-Stage Renal Disease. <i>Blood Purification</i> , 2003, 21, 29-36.	0.9	76
64	Predictors of Cardiovascular Death in ESRD. <i>Seminars in Nephrology</i> , 2005, 25, 358-362.	0.6	76
65	Adipose tissue as a source of inflammatory cytokines in health and disease: Focus on end-stage renal disease. <i>Kidney International</i> , 2003, 63, S65-S68.	2.6	72
66	Physical Performance and Clinical Outcomes in Dialysis Patients: A Secondary Analysis of the Excite Trial. <i>Kidney and Blood Pressure Research</i> , 2014, 39, 205-211.	0.9	72
67	Sleep Apnea in Renal Patients. <i>Journal of the American Society of Nephrology: JASN</i> , 2001, 12, 2854-2859.	3.0	72
68	Within-Patient Reproducibility of the Aldosterone:Renin Ratio in Primary Aldosteronism. <i>Hypertension</i> , 2010, 55, 83-89.	1.3	70
69	Association between Resistin Levels and All-Cause and Cardiovascular Mortality: A New Study and a Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2015, 10, e0120419.	1.1	69
70	The 2020 Italian Society of Arterial Hypertension (SIIA) practical guidelines for the management of primary aldosteronism. <i>International Journal of Cardiology: Hypertension</i> , 2020, 5, 100029.	2.2	69
71	Diagnostic value of troponin T for alterations in left ventricular mass and function in dialysis patients. <i>Kidney International</i> , 2002, 62, 1884-1890.	2.6	66
72	Long-term visit-to-visit office blood pressure variability increases the risk of adverse cardiovascular outcomes in patients with chronic kidney disease. <i>Kidney International</i> , 2013, 84, 381-389.	2.6	65

#	ARTICLE	IF	CITATIONS
73	Association of IL-6 and a Functional Polymorphism in the IL-6 Gene with Cardiovascular Events in Patients with CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 232-240.	2.2	64
74	Quantitative Value of Aldosteroneâ€Renin Ratio for Detection of Aldosteroneâ€Producing Adenoma: The Aldosteroneâ€Renin Ratio for Primary Aldosteronism (AQUARR) Study. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	64
75	Hypertension in Chronic Kidney Disease Part 1. <i>Hypertension</i> , 2016, 67, 1093-1101.	1.3	63
76	Inflammatory proteins as predictors of cardiovascular disease in patients with end-stage renal disease. <i>Nephrology Dialysis Transplantation</i> , 2004, 19, v67-v72.	0.4	62
77	Circulating soluble receptor of advanced glycation end product inversely correlates with atherosclerosis in patients with chronic kidney disease. <i>Kidney International</i> , 2010, 77, 225-231.	2.6	60
78	Efficacy of a remote web-based lung ultrasound training for nephrologists and cardiologists: a LUST trial sub-project. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 1982-1988.	0.4	60
79	Vitamin D receptor (VDR) gene polymorphism is associated with left ventricular (LV) mass and predicts left ventricular hypertrophy (LVH) progression in end-stage renal disease (ESRD) patients. <i>Journal of Bone and Mineral Research</i> , 2010, 25, 313-319.	3.1	59
80	Effect of a home based, low intensity, physical exercise program in older adults dialysis patients: a secondary analysis of the EXCITE trial. <i>BMC Geriatrics</i> , 2018, 18, 248.	1.1	59
81	Hepatocyte growth factor predicts survival and relates to inflammation and intima media thickness in end-stage renal disease. <i>American Journal of Kidney Diseases</i> , 2000, 36, 945-952.	2.1	56
82	Assessment of obesity in chronic kidney disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2012, 21, 641-646.	1.0	56
83	Hypertension in dialysis patients. <i>Journal of Hypertension</i> , 2017, 35, 657-676.	0.3	56
84	Low triiodothyronine and cardiomyopathy in patients with end-stage renal disease. <i>Journal of Hypertension</i> , 2006, 24, 2039-2046.	0.3	55
85	Left ventricular hypertrophy and nocturnal hypoxemia in hemodialysis patients. <i>Journal of Hypertension</i> , 2001, 19, 287-293.	0.3	52
86	Association of a Polymorphism in a Gene Encoding a Urate Transporter with CKD Progression. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014, 9, 1059-1065.	2.2	51
87	Asymptomatic Pulmonary Congestion and Physical Functioning in Hemodialysis Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 1343-1348.	2.2	50
88	Biomarkers of Left Atrial Volume. <i>Hypertension</i> , 2009, 54, 818-824.	1.3	49
89	Physical activity in chronic kidney disease and the EXerCise Introduction To Enhance trial. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, ii18-ii22.	0.4	49
90	Serum uric acid, predicts heart failure in a large Italian cohort: search for a cut-off value the URic acid Right for heArt Health study. <i>Journal of Hypertension</i> , 2021, 39, 62-69.	0.3	49

#	ARTICLE	IF	CITATIONS
91	Prospective Study of Neuropeptide Y as an Adverse Cardiovascular Risk Factor in End-Stage Renal Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2003, 14, 2611-2617.	3.0	48
92	Left Ventricular Systolic Function Monitoring in Asymptomatic Dialysis Patients: A Prospective Cohort Study. <i>Journal of the American Society of Nephrology: JASN</i> , 2006, 17, 1460-1465.	3.0	48
93	Heart valve calcifications, survival, and cardiovascular risk in hemodialysis patients. <i>American Journal of Kidney Diseases</i> , 2004, 43, 479-484.	2.1	47
94	Relationships between diuretic-related hyperuricemia and cardiovascular events: data from the URic acid Right for heArt Health study. <i>Journal of Hypertension</i> , 2021, 39, 333-340.	0.3	46
95	Adipose tissue cytokines, insulin sensitivity, inflammation, and cardiovascular outcomes in end-stage renal disease patients. , 2005, 15, 125-130.		45
96	Uric Acid, Hypertension, and Cardiovascular and Renal Complications. <i>Current Hypertension Reports</i> , 2013, 15, 531-537.	1.5	45
97	A randomized multicenter trial on a lung ultrasoundâ€‘guided treatment strategy in patients on chronic hemodialysis with high cardiovascular risk. <i>Kidney International</i> , 2021, 100, 1325-1333.	2.6	45
98	Mendelian Randomization: A New Approach to Studying Epidemiology in ESRD. <i>American Journal of Kidney Diseases</i> , 2006, 47, 332-341.	2.1	43
99	Hyperhomocysteinemia and arteriovenous fistula thrombosis in hemodialysis patients. <i>American Journal of Kidney Diseases</i> , 2005, 45, 702-707.	2.1	42
100	AGEs and carbonyl stress: potential pathogenetic factors of longâ€‘term uraemic complications. <i>Nephrology Dialysis Transplantation</i> , 2000, 15, 7-11.	0.4	41
101	Rate of Atherosclerotic Plaque Formation Predicts Cardiovascular Events in ESRD. <i>Journal of the American Society of Nephrology: JASN</i> , 2008, 19, 757-763.	3.0	41
102	Adiponectin and Leptin in Chronic Kidney Disease: Causal Factors or Mere Risk Markers?. , 2011, 21, 87-91.		41
103	The Role of Deconditioning in the End-Stage Renal Disease Myopathy: Physical Exercise Improves Altered Resting Muscle Oxygen Consumption. <i>American Journal of Nephrology</i> , 2015, 41, 329-336.	1.4	41
104	Inflammation as a Mediator of the Link between Mild to Moderate Renal Insufficiency and Endothelial Dysfunction in Essential Hypertension. <i>Journal of the American Society of Nephrology: JASN</i> , 2006, 17, S64-S68.	3.0	39
105	Longitudinal Analysis of Vascular Function and Biomarkers of Metabolic Bone Disorders before and after Renal Transplantation. <i>American Journal of Nephrology</i> , 2013, 37, 126-134.	1.4	39
106	Blood Pressure Variability, Mortality, and Cardiovascular Outcomes in CKD Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019, 14, 233-240.	2.2	39
107	HYPERTENSION IN HEMODIALYSIS PATIENTS: Cardiac Consequences of Hypertension in Hemodialysis Patients. <i>Seminars in Dialysis</i> , 2004, 17, 299-303.	0.7	38
108	The <i>ENPP1</i> Q121 Variant Predicts Major Cardiovascular Events in High-Risk Individuals. <i>Diabetes</i> , 2011, 60, 1000-1007.	0.3	37

#	ARTICLE	IF	CITATIONS
109	Obesity and CKD progression: hard facts on fat CKD patients. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, iv105-iv108.	0.4	36
110	Sympathetic neural overdrive in congestive heart failure and its correlates. <i>Journal of Hypertension</i> , 2019, 37, 1746-1756.	0.3	34
111	Association of uric acid with kidney function and albuminuria: the Uric Acid Right for heArt Health (URRAH) Project. <i>Journal of Nephrology</i> , 2022, 35, 211-221.	0.9	34
112	Obesity and nephrology: results of a knowledge and practice pattern survey. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, iv99-iv104.	0.4	33
113	Searching for biomarker patterns characterizing carotid atherosclerotic burden in patients with reduced renal function. <i>Nephrology Dialysis Transplantation</i> , 2007, 22, 3521-3526.	0.4	32
114	Lung Congestion as a Risk Factor in End-Stage Renal Disease. <i>Blood Purification</i> , 2013, 36, 184-191.	0.9	32
115	Comparative effectiveness of different antihypertensive agents in kidney transplantation: a systematic review and meta-analysis. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 878-887.	0.4	32
116	High estimated pulmonary artery systolic pressure predicts adverse cardiovascular outcomes in stage 2-4 chronic kidney disease. <i>Kidney International</i> , 2015, 88, 130-136.	2.6	31
117	The importance of including uric acid in the definition of metabolic syndrome when assessing the mortality risk. <i>Clinical Research in Cardiology</i> , 2021, 110, 1073-1082.	1.5	31
118	Ultrafiltration intensification in hemodialysis patients improves hypertension but increases AV fistula complications and cardiovascular events.. <i>Journal of Nephrology</i> , 2011, 24, 465-473.	0.9	31
119	Resistin and all-cause and cardiovascular mortality: effect modification by adiponectin in end-stage kidney disease patients. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, iv181-iv187.	0.4	30
120	Moderator's view: Ambulatory blood pressure monitoring and home blood pressure for the prognosis, diagnosis and treatment of hypertension in dialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 1443-1448.	0.4	30
121	Clinical Epidemiology of Major Nontraditional Risk Factors in Peritoneal Dialysis Patients. <i>Peritoneal Dialysis International</i> , 2005, 25, 84-87.	1.1	29
122	Intact FGF23 and ð±ð±klotho during acute inflammation/sepsis in CKD patients. <i>European Journal of Clinical Investigation</i> , 2016, 46, 234-241.	1.7	28
123	Pulse Wave Velocity and Prognosis in End-Stage Kidney Disease. <i>Hypertension</i> , 2018, 71, 1126-1132.	1.3	28
124	Hepatocyte Growth Factor and Left Ventricular Geometry in End-Stage Renal Disease. <i>Hypertension</i> , 2003, 41, 88-92.	1.3	27
125	The GLU298ASP variant of nitric oxide synthase interacts with asymmetric dimethyl arginine in determining cardiovascular mortality in patients with end-stage renal disease. <i>Journal of Hypertension</i> , 2005, 23, 1825-1830.	0.3	27
126	Epidemiology of CKD Regression in Patients under Nephrology Care. <i>PLoS ONE</i> , 2015, 10, e0140138.	1.1	27

#	ARTICLE	IF	CITATIONS
127	A Genetic Marker of Uric Acid Level, Carotid Atherosclerosis, and Arterial Stiffness: A Family-Based Study. <i>American Journal of Kidney Diseases</i> , 2015, 65, 294-302.	2.1	27
128	Nocturnal Hypertension and Altered Nightâ€“Day BP Profile and Atherosclerosis in Renal Transplant Patients. <i>Transplantation</i> , 2016, 100, 2211-2218.	0.5	27
129	Short-term blood pressure variability in nondialysis chronic kidney disease patients. <i>Journal of Hypertension</i> , 2018, 36, 2398-2405.	0.3	26
130	Sympathetic nerve traffic overactivity in chronic kidney disease: a systematic review and meta-analysis. <i>Journal of Hypertension</i> , 2021, 39, 408-416.	0.3	25
131	Vascular endothelial growth factor, left ventricular dysfunction and mortality in hemodialysis patients. <i>Journal of Hypertension</i> , 2008, 26, 1875-1882.	0.3	24
132	Urotensin II: a cardiovascular and renal update. <i>Current Opinion in Nephrology and Hypertension</i> , 2008, 17, 199-204.	1.0	24
133	The burden of physical inactivity in chronic kidney disease: is there an exit strategy?. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 2143-2145.	0.4	24
134	FGF23: A Mature Renal and Cardiovascular Risk Factor?. <i>Blood Purification</i> , 2013, 36, 52-57.	0.9	24
135	A Longitudinal Study of Inflammation, CKD-Mineral Bone Disorder, and Carotid Atherosclerosis after Renal Transplantation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 471-479.	2.2	24
136	Neuropeptide Y, left ventricular mass and function in patients with end stage renal disease. <i>Journal of Hypertension</i> , 2003, 21, 1355-1362.	0.3	23
137	Pro-inflammatory cytokines and bone fractures in CKD patients. An exploratory single centre study. <i>BMC Nephrology</i> , 2012, 13, 134.	0.8	23
138	Joint effect of insulin signaling genes on cardiovascular events and on whole body and endothelial insulin resistance. <i>Atherosclerosis</i> , 2013, 226, 140-145.	0.4	23
139	Validity of Vascular Calcification as a Screening Tool and as a Surrogate End Point in Clinical Research. <i>Hypertension</i> , 2015, 66, 3-9.	1.3	23
140	Office, standardized and 24-h ambulatory blood pressure and renal function loss in renal transplant patients. <i>Journal of Hypertension</i> , 2018, 36, 119-125.	0.3	23
141	<i>Chlamydia pneumoniae</i> , overall and cardiovascular mortality in end-stage renal disease (ESRD). <i>Kidney International</i> , 2003, 64, 579-584.	2.6	22
142	Thyroid Function and Clinical Outcomes in Kidney Failure. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2012, 7, 12-14.	2.2	22
143	Immunity in arterial hypertension: associations or causalities?. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 1959-1964.	0.4	22
144	Sodium–glucose co-transporter-2 inhibitors for patients with diabetic and nondiabetic chronic kidney disease: a new era has already begun. <i>Journal of Hypertension</i> , 2021, 39, 1090-1097.	0.3	22

#	ARTICLE	IF	CITATIONS
145	Hyperkalemia in Chronic Kidney Disease in the New Era of Kidney Protection Therapies. <i>Drugs</i> , 2021, 81, 1467-1489.	4.9	22
146	Urotensin II and Biomarkers of Endothelial Activation and Atherosclerosis in End-Stage Renal Disease. <i>American Journal of Hypertension</i> , 2006, 19, 505-510.	1.0	21
147	Competitive Interaction Between Fibroblast Growth Factor 23 And Asymmetric Dimethylarginine in Patients With CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 935-944.	3.0	21
148	Subclinical pulmonary congestion is prevalent in nephrotic syndrome. <i>Kidney International</i> , 2016, 89, 421-428.	2.6	21
149	Prevalence and control of hypertension by 48-h ambulatory blood pressure monitoring in haemodialysis patients: a study by the European Cardiovascular and Renal Medicine (EURECA-m) working group of the ERA-EDTA. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 1542-1548.	0.4	21
150	Nocturnal Hypoxemia: A Neglected Cardiovascular Risk Factor in End-Stage Renal Disease?. <i>Blood Purification</i> , 2002, 20, 120-123.	0.9	20
151	Low parathyroid hormone and pentosidine in hemodialysis patients. <i>American Journal of Kidney Diseases</i> , 2002, 40, 810-815.	2.1	20
152	Ramipril Lowers Plasma FGF-23 in Patients with Diabetic Nephropathy. <i>American Journal of Nephrology</i> , 2014, 40, 208-214.	1.4	20
153	Respiratory muscle impairment in dialysis patients: can minimal dose of exercise limit the damage? A Preliminary study in a sample of patients enrolled in the EXCITE trial. <i>Journal of Nephrology</i> , 2016, 29, 863-869.	0.9	20
154	Identification of a plausible serum uric acid cut-off value as prognostic marker of stroke: the Uric Acid Right for Heart Health (URRAH) study. <i>Journal of Human Hypertension</i> , 2022, 36, 976-982.	1.0	20
155	Urotensin II and Cardiomyopathy in End-Stage Renal Disease. <i>Hypertension</i> , 2008, 51, 326-333.	1.3	19
156	Long-term blood pressure monitoring by office and 24-h ambulatory blood pressure in renal transplant patients: a longitudinal study. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 1558-1564.	0.4	19
157	Urotensin II in end-stage renal disease: an inverse correlate of sympathetic function and cardiac natriuretic peptides. <i>Journal of Nephrology</i> , 2005, 18, 727-32.	0.9	19
158	Hypertension as a cardiovascular risk factor in end-stage renal failure. <i>Current Hypertension Reports</i> , 2002, 4, 381-386.	1.5	18
159	The E-selectin gene polymorphism and carotid atherosclerosis in end-stage renal disease. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 1921-1926.	0.4	18
160	Neuropeptide Y and chronic kidney disease progression: a cohort study. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 1805-1812.	0.4	18
161	Blood pressure monitoring in kidney transplantation: a systematic review on hypertension and target organ damage. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 1326-1346.	0.4	18
162	Serum Uric Acid and Kidney Disease Measures Independently Predict Cardiovascular and Total Mortality: The Uric Acid Right for Heart Health (URRAH) Project. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 713652.	1.1	18

#	ARTICLE	IF	CITATIONS
163	The MAURO study: baseline characteristics and compliance with guidelines targets. <i>Journal of Nephrology</i> , 2012, 25, 1081-1090.	0.9	18
164	Obesity, diabetes, adiponectin and the kidney: a podocyte affair. <i>Nephrology Dialysis Transplantation</i> , 2008, 23, 3767-3770.	0.4	17
165	Fitness for Entering a Simple Exercise Program and Mortality: A Study Corollary to the Exercise Introduction to Enhance Performance in Dialysis (Excite) Trial. <i>Kidney and Blood Pressure Research</i> , 2014, 39, 197-204.	0.9	17
166	Mapping Progress in Reducing Cardiovascular Risk with Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 1432-1434.	2.2	17
167	Effects of Sevelamer Carbonate in Patients With CKD and Proteinuria: The ANSWER Randomized Trial. <i>American Journal of Kidney Diseases</i> , 2019, 74, 338-350.	2.1	17
168	Measuring asymmetric dimethylarginine (ADMA) in CKD: a comparison between enzyme-linked immunosorbent assay and liquid chromatography-electrospray tandem mass spectrometry. <i>Journal of Nephrology</i> , 2012, 25, 1016-1022.	0.9	17
169	Sympathetic nerve traffic and blood pressure changes after bilateral renal denervation in resistant hypertension: a time-integrated analysis. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, 1351-1356.	0.4	16
170	Uric acid in chronic kidney disease: the quest for causality continues. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 193-195.	0.4	16
171	Hypertension in kidney transplantation: a consensus statement of the "hypertension and the kidney"™ working group of the European Society of Hypertension. <i>Journal of Hypertension</i> , 2021, 39, 1513-1521.	0.3	16
172	Leptin and biochemical markers of bone turnover in dialysis patients. <i>Journal of Nephrology</i> , 2004, 17, 253-60.	0.9	16
173	The fat-mass and obesity-associated gene (FTO) predicts mortality in chronic kidney disease of various severity. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, iv58-iv62.	0.4	15
174	eNOS and Caveolin-1 Gene Polymorphisms Interaction and Intima Media Thickness: A Proof of Concept Study in ESRD Patients. <i>American Journal of Hypertension</i> , 2012, 25, 103-108.	1.0	15
175	The use of echocardiography in observational clinical trials: the EURECA-m registry. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 19-23.	0.4	15
176	Pleiotropic effects of angiotensin II blockers in hemodialysis patients: myth or reality?. <i>Kidney International</i> , 2014, 86, 469-471.	2.6	15
177	Snoring Amplifies the Risk of Heart Failure and Mortality in Dialysis Patients. <i>American Journal of Nephrology</i> , 2014, 39, 536-542.	1.4	15
178	Treatment-resistant hypertension in the hemodialysis population: a 44-h ambulatory blood pressure monitoring-based study. <i>Journal of Hypertension</i> , 2020, 38, 1849-1856.	0.3	15
179	Can the assessment of ultrasound lung water in haemodialysis patients be simplified?. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 2321-2326.	0.4	15
180	Serum uric acid levels threshold for mortality in diabetic individuals: The URic acid Right for heArt Health (URRAH) project. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2022, 32, 1245-1252.	1.1	15

#	ARTICLE	IF	CITATIONS
181	Atherosclerosis and the Glu298Asp Polymorphism of the eNOS Gene in White Patients With End-Stage Renal Disease. <i>American Journal of Hypertension</i> , 2005, 18, 1549-1555.	1.0	14
182	Obesity and the Epidemiology and Prevention of Kidney Disease: Waist Circumference Versus Body Mass Index. <i>American Journal of Kidney Diseases</i> , 2011, 58, 157-159.	2.1	14
183	Optimizing hypertension management in renal transplantation: a call to action. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, 1959-1962.	0.4	14
184	Serum Erythroferrone Levels Associate with Mortality and Cardiovascular Events in Hemodialysis and in CKD Patients: A Two Cohorts Study. <i>Journal of Clinical Medicine</i> , 2019, 8, 523.	1.0	14
185	Assessment of hypertension in kidney transplantation by ambulatory blood pressure monitoring: a systematic review and meta-analysis. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 31-42.	1.4	14
186	Traditional and nontraditional risk factors as predictors of cerebrovascular events in patients with end stage renal disease. <i>Journal of Hypertension</i> , 2010, 28, 2468-2474.	0.3	14
187	Reappraisal in two European cohorts of the prognostic power of left ventricular mass index in chronic kidney failure. <i>Kidney International</i> , 2017, 91, 704-710.	2.6	13
188	Lung congestion as a hidden threat in end-stage kidney disease: a call to action. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 2657-2660.	0.4	12
189	A polymorphism in a major antioxidant gene (Kelch-like ECH-associated protein 1) predicts incident cardiovascular events in chronic kidney disease patients. <i>Journal of Hypertension</i> , 2016, 34, 928-934.	0.3	12
190	Lung Ultrasound-Guided Dry-Weight Reduction in Hemodialysis Patients Does Not Affect Short-Term Blood Pressure Variability. <i>American Journal of Hypertension</i> , 2019, 32, 786-795.	1.0	12
191	Intravenous iron therapy and the cardiovascular system: risks and benefits. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 1067-1076.	1.4	12
192	The association of uric acid with mortality modifies at old age: data from the uric acid right for heart health (URRAH) study. <i>Journal of Hypertension</i> , 2022, 40, 704-711.	0.3	12
193	Asymmetric and Symmetric Dimethylarginine and Sympathetic Nerve Traffic after Renal Denervation in Patients with Resistant Hypertension. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 1560-1567.	2.2	11
194	Soluble Urokinase Plasminogen Activator Receptor (suPAR) and All-Cause and Cardiovascular Mortality in Diverse Hemodialysis Patients. <i>Kidney International Reports</i> , 2018, 3, 1100-1109.	0.4	11
195	Neuropeptide Y as a risk factor for cardiorenal disease and cognitive dysfunction in chronic kidney disease: translational opportunities and challenges. <i>Nephrology Dialysis Transplantation</i> , 2021, 37, ii14-ii23.	0.4	11
196	Neuropeptide Y predicts cardiovascular events in chronic kidney disease patients. <i>Journal of Hypertension</i> , 2019, 37, 1359-1365.	0.3	10
197	Prognostic values of left ventricular mass index in chronic kidney disease patients. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 665-672.	0.4	10
198	Sleep Apnea as a Cardiorenal Risk Factor in CKD and Renal Transplant Patients. <i>Blood Purification</i> , 2021, 50, 642-648.	0.9	10

#	ARTICLE	IF	CITATIONS
199	An Additive Effect of Endothelial Nitric Oxide Synthase Gene Polymorphisms Contributes to the Severity of Atherosclerosis in Patients on Dialysis. <i>American Journal of Hypertension</i> , 2007, 20, 758-763.	1.0	9
200	Neuropeptide Y and Markers of Osteoblast Activity in Dialysis Patients: A Cross-Sectional Study. <i>American Journal of Kidney Diseases</i> , 2007, 50, 1001-1008.	2.1	9
201	Clinical Implications of Elevated Asymmetric Dimethylarginine in Chronic Kidney Disease and End-Stage Renal Disease. , 2009, 19, 25-28.		9
202	Neuropeptide Y receptor Y2 gene polymorphism interacts with plasma neuropeptide Y levels in predicting left ventricular hypertrophy in dialysis patients. <i>Journal of Hypertension</i> , 2010, 28, 1745-1751.	0.3	9
203	Insulin resistance and left ventricular hypertrophy in end-stage renal disease: association between the ENPP1 gene and left ventricular concentric remodelling. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 661-666.	0.4	9
204	High heart rate amplifies the risk of cardiovascular mortality associated with elevated uric acid. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 1501-1509.	0.8	9
205	Heart rate, age and the risk of progression to kidney failure in patients with CKD. <i>Journal of Nephrology</i> , 2012, 25, 20-27.	0.9	9
206	Asymmetric dimethylarginine (ADMA) as a cardiovascular risk factor in end-stage renal disease (ESRD). <i>European Journal of Clinical Pharmacology</i> , 2006, 62, 131-135.	0.8	8
207	CARDIOVASCULAR AND SURVIVAL PARADOXES IN DIALYSIS PATIENTS: It Is Important to Lower Homocysteine in Dialysis Patients. <i>Seminars in Dialysis</i> , 2007, 20, 530-533.	0.7	8
208	Aldosterone, mortality, cardiovascular events and reverse epidemiology in end stage renal disease. <i>European Journal of Clinical Investigation</i> , 2015, 45, 1077-1086.	1.7	8
209	The overdriven glomerulus as a cardiovascular risk factor. <i>Kidney International</i> , 2018, 93, 13-15.	2.6	8
210	Circulating adiponectin modifies the FGF23 response to vitamin D receptor activation: a post hoc analysis of a double-blind, randomized clinical trial. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 1764-1769.	0.4	8
211	Validation of echocardiographic criteria for the clinical diagnosis of heart failure in chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 653-660.	0.4	8
212	Urine chloride self-measurement to monitor sodium chloride intake in patients with chronic kidney disease. <i>Clinical Chemistry and Laboratory Medicine</i> , 2019, 57, 1162-1168.	1.4	8
213	FGF23 and the PTH response to paricalcitol in chronic kidney disease. <i>European Journal of Clinical Investigation</i> , 2020, 50, e13196.	1.7	8
214	Sleep-Disordered Breathing and 24-Hour Ambulatory Blood Pressure Monitoring in Renal Transplant Patients: Longitudinal Study. <i>Journal of the American Heart Association</i> , 2020, 9, e016237.	1.6	8
215	Ageing and Left Ventricular Mass and Function in People with End-Stage Renal Disease. <i>Journal of the American Geriatrics Society</i> , 2011, 59, 1636-1641.	1.3	7
216	Comment accompanying: obstructive sleep apnoea: a stand-alone risk factor for chronic kidney disease by Chou Yu-Ting. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 2072-2074.	0.4	7

#	ARTICLE	IF	CITATIONS
217	Joint effect of insulin signaling genes on all-cause mortality. <i>Atherosclerosis</i> , 2014, 237, 639-644.	0.4	7
218	Highlights of the 2015 ERA-EDTA congress: chronic kidney disease, hypertension. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 1044-1046.	0.4	7
219	Effect of Vitamin D Receptor Activation on the AGE/RAGE System and Myeloperoxidase in Chronic Kidney Disease Patients. <i>Oxidative Medicine and Cellular Longevity</i> , 2017, 2017, 1-7.	1.9	7
220	Lung ultrasound to detect and monitor pulmonary congestion in patients with acute kidney injury in nephrology wards: a pilot study. <i>Journal of Nephrology</i> , 2020, 33, 335-341.	0.9	7
221	Excess volume removal following lung ultrasound evaluation decreases central blood pressure and pulse wave velocity in hemodialysis patients: a LUST sub-study. <i>Journal of Nephrology</i> , 2020, 33, 1289-1300.	0.9	7
222	The MAURO study: multiple intervention and audit in renal diseases to optimize care. <i>Journal of Nephrology</i> , 2008, 21, 20-2.	0.9	7
223	Chronic Kidney Disease (CKD) as a Systemic Disease: Whole Body Autoregulation and Inter-Organ Cross-Talk. <i>Kidney and Blood Pressure Research</i> , 2014, 39, 134-141.	0.9	6
224	Cardiovascular protection by β -blockade in hypertensive haemodialysis patients: the Hypertension in Haemodialysis Patients Treated With Atenolol or Lisinopril (HDPAL) trial. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 483-485.	0.4	6
225	Moderator's view: Phosphate binders in chronic kidney disease patients: a clear "No" at the moment, but stay tuned. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, gfv404.	0.4	6
226	Physical exercise in haemodialysis patients: time to start. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 1196-1198.	0.4	6
227	The sirtuin1 gene associates with left ventricular myocardial hypertrophy and remodeling in two chronic kidney disease cohorts. <i>Journal of Hypertension</i> , 2018, 36, 1705-1711.	0.3	6
228	Vitamin D receptor activation raises soluble thrombomodulin levels in chronic kidney disease patients: a double blind, randomized trial. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 819-824.	0.4	6
229	Epidemiology of hyperkalemia in CKD patients under nephrological care: a longitudinal study. <i>Internal and Emergency Medicine</i> , 2021, 16, 1803-1811.	1.0	6
230	Left ventricular hypertrophy in chronic kidney disease. , 2015, , 837-852.		6
231	Soluble E-Selectin Is an Inverse and Independent Predictor of Left Ventricular Wall Thickness in End-Stage Renal Disease Patients. <i>Nephron Clinical Practice</i> , 2010, 114, c74-c80.	2.3	5
232	Salt and the heart in chronic kidney disease: an atrial connection. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 2210-2211.	0.4	5
233	Intact FGF23 and β -klotho during acute inflammation/sepsis in CKD patients. <i>European Journal of Clinical Investigation</i> , 2017, 47, 470-472.	1.7	5
234	Optimizing hypertension management in renal transplantation. <i>Journal of Hypertension</i> , 2017, 35, 2335-2338.	0.3	5

#	ARTICLE	IF	CITATIONS
235	Long-Term Changes in Sleep Disordered Breathing in Renal Transplant Patients: Relevance of the BMI. <i>Journal of Clinical Medicine</i> , 2020, 9, 1739.	1.0	5
236	Detecting and Treating Lung Congestion with Kidney Failure. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, 17, 757-765.	2.2	5
237	Phosphate Binders and Clinical Outcomes in Patients with Stage 5D Chronic Kidney Disease. <i>Seminars in Dialysis</i> , 2015, 28, 587-593.	0.7	4
238	Norepinephrine, left ventricular disorders and volume excess in ESRD. <i>Journal of Nephrology</i> , 2015, 28, 729-737.	0.9	4
239	The dominant prognostic value of physical functioning among quality of life domains in end-stage kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2018, 35, 170-175.	0.4	4
240	Inflammation is an amplifier of lung congestion by high lv filling pressure in hemodialysis patients: a longitudinal study. <i>Journal of Nephrology</i> , 2020, 33, 583-590.	0.9	4
241	Ambulatory blood pressure changes with lung ultrasound-guided dry-weight reduction in hypertensive hemodialysis patients: 12-month results of a randomized controlled trial. <i>Journal of Hypertension</i> , 2021, 39, 1444-1452.	0.3	4
242	Tissue inhibitor of metalloproteinases (TIMP-1), genetic markers of insulin resistance and cardiomyopathy in patients with kidney failure. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 2440-2445.	0.4	3
243	Vitamin D and methylarginines in chronic kidney disease (CKD). <i>PLoS ONE</i> , 2017, 12, e0185449.	1.1	3
244	Lung ultrasound-guided dry-weight reduction and echocardiographic changes in clinically euvolemic hypertensive hemodialysis patients: 12-month results of a randomized controlled trial. <i>Hellenic Journal of Cardiology</i> , 2022, 64, 1-6.	0.4	3
245	Value of Troponin T as a Screening Test for Left Ventricular Hypertrophy in CKD. <i>American Journal of Kidney Diseases</i> , 2013, 61, 689-691.	2.1	2
246	Should we extend the application of more frequent dialysis schedules? A 'yes' and a hopeful 'no'. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 29-32.	0.4	2
247	Arterial Stiffness as a Cardiovascular Risk Factor in Stage 5D Chronic Kidney Disease Patients: An Age Affair. <i>American Journal of Nephrology</i> , 2017, 45, 69-71.	1.4	2
248	Physical functioning and mortality in very old patients on dialysis. <i>Archives of Gerontology and Geriatrics</i> , 2019, 85, 103918.	1.4	2
249	Guest Editor: Rajiv Agarwal: Cardiovascular Risk Profile Assessment and Medication Control Should Come First. <i>Seminars in Dialysis</i> , 2007, 20, 405-408.	0.7	1
250	Fluid overload and post-dialysis hypertension. <i>Nature Reviews Nephrology</i> , 2014, 10, 623-624.	4.1	1
251	Cocoa Flavanols. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 9-11.	2.2	1
252	FP720SLEEP DISORDERED BREATHING IN RENAL TRANSPLANT PATIENTS: A LONGITUDINAL STUDY. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i288-i288.	0.4	1

#	ARTICLE	IF	CITATIONS
253	A new therapy for sleep apnea?. Journal of Hypertension, 2021, 39, 1098-1101.	0.3	1
254	Thyroid, Renal Function, and Cardiac Outcome. , 2009, , 191-201.		1
255	Early morning hemodynamic changes and left ventricular hypertrophy and mortality in hemodialysis patients. Journal of Nephrology, 2022, , .	0.9	1
256	Clinical News. British Journal of Hospital Medicine (London, England: 2005), 2017, 78, 368-371.	0.2	0
257	Role of Novel Biomarkers in Chronic Kidney Disease: Urotensin II. , 2010, , 299-308.		0
258	Thyroid Dysfunction and Cardiovascular Disease in Chronic Kidney Disease. , 2020, , 327-338.		0